Trans-femoral Versus Trans-carotid Access for Transcatheter Aortic Valve Replacement: an Updated Systematic Review and Meta-analysis
Overview
Authors
Affiliations
This meta-analysis aims to shed light on any primacy the -carotid (TC-TAVR) access may have over the -femoral access (TF-TAVR) for those undergoing transcatheter aortic valve replacement (TAVR). PubMed/MEDLINE and Cochrane Library were searched, from inception to March 2023 retrieving seven adjusted studies with a total of 6609 patients, of which 5048 underwent TF-TAVR while 1561 underwent TC-TAVR. No divergence in risk of mortality, major bleeding or stroke/transient ischemic attack in TC-TAVR when compared with TF-TAVR was found. In TC-TAVR, the risk of vascular complications was low (OR: 0.51, 95% CI: 0.32-0.83, p = 0.003) as compared with TF-TAVR. As of this analysis, the viability of TC-TAVR as first alternative to TF-TAVR is plausible.
Zhao Y, Chen T, Yang L, Mao W, Wan Y, Zhang L Front Cardiovasc Med. 2024; 11:1428083.
PMID: 39156135 PMC: 11327814. DOI: 10.3389/fcvm.2024.1428083.